title: Stratification of treatment intensity in relapsed pediatric Hodgkin lymphoma.
abstract: Risk-adapted, response-based therapies for pediatric Hodgkin lymphoma have resulted in 5-year survival exceeding 90%. Although high-dose chemotherapy and autologous hematopoietic stem cell transplantation (AHSCT) are considered standard for most patients with relapsed or refractory Hodgkin lymphoma, a subset of children with low risk relapse do not require AHSCT for cure. Currently there are no widely accepted criteria defining who should receive standard dose chemotherapy and/or radiotherapy, nor is there a standardized treatment regimen. We propose a risk-stratified, response-based algorithm for children with relapsed or refractory Hodgkin lymphoma that is based on a critical appraisal of published outcomes and prognostic factors.
authors: Division of Pediatric Hematology and Oncology, Midwest Children's Cancer Center, Milwaukee, Wisconsin.
authors: Paul D
authors: PD
authors: Harker-Murray
authors: Richard A
authors: RA
authors: Drachtman
authors: David C
authors: DC
authors: Hodgson
authors: Allen Russell
authors: AR
authors: Chauvenet
authors: Kara M
authors: KM
authors: Kelly
authors: Peter David
authors: PD
authors: Cole
mesh_terms: D003131:Combined Modality Therapy; D006689:Hodgkin Disease / Q000628:therapy*; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000628:therapy*
keywords: Hodgkin lymphoma; chemotherapy; hematopoietic cell transplant; pediatric oncology; relapse